explore -WSS

explore

author：leisure time 2025-09-27 22:49:22 - browse：66819

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

leisure time

WSS

Why the world’s most expensive drug might be worth the price

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Decaf coffee targeted by food safety group under obscure FDA rule

Washington mulls new rules to avert another Change Healthcare

Food as medicine: Medically tailored meals may get standardized

ASCO: Palliative care found as helpful given virtually as in person

focus

explore

leisure time

23andMe had bad news about my health. I wish a person had delivered it

Decaf coffee targeted by food safety group under obscure FDA rule

Wildfire smoke exposes gaps in outdoor worker protections

Merck drug for rare lung condition set for approval in U.S.

At least 13 dead in Texas as scorching temps continue

Primary care physicians play key roles in Alzheimer's management

The high cost of giving birth even with insurance

There's no autism epidemic. It's an autism diagnosis epidemic

Peter Hotez and the public health issue of online harassment

Food as medicine: Medically tailored meals may get standardized

focus

There's no autism epidemic. It's an autism diagnosis epidemic

FDA's naming rule on biosimilars has undermined competition

Readout LOUD podcast: mifepristone case, GLP

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Merck, Vertex, and Viking updates

At ASCO, AstraZeneca reports strong data for breast cancer drug

leisure time

leisure time

knowledge

hotspot